In:
Cancer, Wiley, Vol. 121, No. 16 ( 2015-08-15), p. 2720-2729
Kurzfassung:
In a prospective biomarker study of patients with nasopharyngeal cancer, plasma Epstein‐Barr virus DNA is validated as the most significant prognostic biomarker for use in selecting high‐risk patients for adjuvant therapy. The ERCC1 C118T genotype may help to identify a favorable subgroup of patients (approximately 7%) with plasma Epstein‐Barr virus DNA‐negative nasopharyngeal cancer who have an excellent prognosis and can be spared the toxicities of further therapy.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v121.16
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2015
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1